Publications:417
Video Visit Available
Accepting New Patients
Book an Appointment
About Me
Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. He joined Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn's & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital's Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School.
A longtime advocate for the continued translational research in Crohn's disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. He was among the first to report the efficacy of infliximab-a drug used to treat autoimmune diseases-in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials. Dr. Sands was also principal investigator for the landmark ACCENT II study, an international project that demonstrated the efficacy of the anti-tumor necrosis factor antibody infliximab as a long-term treatment for fistulizing Crohn's disease.
Dr. Sands' research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island, a project that is funded by the Centers for Disease Control and Prevention.,
A leader in several major professional organizations, Dr. Sands has served as the chair of the Clinical Research Alliance of the Crohn's Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA), and chair of the International Organization for the Study of IBD. He is an AGA Fellow (AGAF) and a fellow of the American College of Gastroenterology (FACG). In 2006 he was named Humanitarian of the Year by the New England Chapter of the Crohn's and Colitis Foundation of America, and the Massachusetts General Physician Organization honored him for "Excellence in Action" in recognition of his distinguished patient care.
His work has appeared in several leading peer-reviewed journals, including the New England Journal of Medicine, Gastroenterology and Gut. Dr. Sands is also a reviewer for many prominent publications, including the New England Journal of Medicine. Dr. Sands served as an Associate Editor for the field's leading journal, Gastroenterology, from 2011 to 2016.
Dr. Sands received his medical degree at Boston University School of Medicinein Massachusetts and completed a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. He then completed clinical and research fellowships at the Massachusetts General Hospital. In 2001 Dr. Sands also earned a Master of Science in Epidemiology at Harvard School of Public Health.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- The Mount Sinai Hospital
- Mount Sinai West
About Me
Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. He joined Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn's & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital's Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School.
A longtime advocate for the continued translational research in Crohn's disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. He was among the first to report the efficacy of infliximab-a drug used to treat autoimmune diseases-in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials. Dr. Sands was also principal investigator for the landmark ACCENT II study, an international project that demonstrated the efficacy of the anti-tumor necrosis factor antibody infliximab as a long-term treatment for fistulizing Crohn's disease.
Dr. Sands' research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island, a project that is funded by the Centers for Disease Control and Prevention.,
A leader in several major professional organizations, Dr. Sands has served as the chair of the Clinical Research Alliance of the Crohn's Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA), and chair of the International Organization for the Study of IBD. He is an AGA Fellow (AGAF) and a fellow of the American College of Gastroenterology (FACG). In 2006 he was named Humanitarian of the Year by the New England Chapter of the Crohn's and Colitis Foundation of America, and the Massachusetts General Physician Organization honored him for "Excellence in Action" in recognition of his distinguished patient care.
His work has appeared in several leading peer-reviewed journals, including the New England Journal of Medicine, Gastroenterology and Gut. Dr. Sands is also a reviewer for many prominent publications, including the New England Journal of Medicine. Dr. Sands served as an Associate Editor for the field's leading journal, Gastroenterology, from 2011 to 2016.
Dr. Sands received his medical degree at Boston University School of Medicinein Massachusetts and completed a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. He then completed clinical and research fellowships at the Massachusetts General Hospital. In 2001 Dr. Sands also earned a Master of Science in Epidemiology at Harvard School of Public Health.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- The Mount Sinai Hospital
- Mount Sinai West
Clinical Focus
- Crohn's Disease
- Gastroenterology
- Inflammatory Bowel Disease
- Ulcerative Colitis
Education
MD, Boston University School of Medicine
Residency, Internal Medicine
Hospital of the University of Pennsylvania
Fellowship, Gastroenterology
Massachusetts General Hospital
Certifications
American Board of Internal Medicine
Awards
2010
Chair, Immunology, Microbiology & Inflammatory Bowel Disease Section
American Gastroenterological Association
2007
Chair, Clinical Research Alliance
Crohn's & Colitis Foundation of America
Fellow
American College of Gastroenterology
Fellow
American Gastroenterological Association
Research
Dr. Sands' research as a clinical investigator focuses on extending basic pathogenetic observations in the inflammatory bowel diseases--Crohn's disease and ulcerative colitis--to translational research and clinical trials. I have been an active investigator in clinical trials of novel agents directed at specific pathophysiologic targets in IBD in all phases of study. His earliest clinical trial work was with infliximab, a chimeric monoclonal anti-tumor necrosis factor antibody that has revolutionized the treatment of Crohn's disease. Dr. Sands was among the first to report on the efficacy of infliximab in ulcerative colitis, later borne out in large randomized controlled trials. Dr. Sands was also overall principal investigator for a large randomized controlled trial of infliximab in fistulizing Crohn's disease, the largest such study to date. In addistion to his work in clinical trials, Dr. Sands's research has included extensive work in observational studies in IBD, including outcomes research and epidemiologic studies. Most recently, he is the principal investigator of OSCCAR, the Ocean State Crohn's & Colitis Area Registry, a novel, prospective, population-based inception cohort of inflammatory bowel disease based in the state of Rhode Island. The goals of this study are to 1) develope robust predictive models for outcomes in IBD, and 2) to elucidate the role of environmental risk factors in the onset of IBD.
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
- Feinstein IBD Clinical Center17 East 102nd Street, 5th Floor, New York, NY, 10029
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints. Sailish Honap, Vipul Jairath, Bruce E. Sands, Parambir S. Dulai, Peter D.R. Higgins, Peter De Cruz, Ana Gutiérrez, Paulo G. Kotze, Byong Duk Ye, Taku Kobayashi, Richard B. Gearry, Pablo A. Olivera, Aurélien Amiot, Mahmoud H. Mosli, Sameer Al Awadhi, Jonas Halfvarson, Kamal V. Patel, Shaji Sebastian, Silvio Danese, Laurent Peyrin-Biroulet. Clinical Gastroenterology and Hepatology
- Distinct perturbances in metabolic pathways associate with disease progression in inflammatory bowel disease. Arno R. Bourgonje, Susanne Ibing, Alexandra E. Livanos, Danielle Y. Ganjian, Carmen Argmann, Bruce E. Sands, Marla C. Dubinsky, Drew S. Helmus, Henrik A. Jacobsen, Lone Larsen, Tine Jess, Mayte Suarez-Fariñas, Bernhard Y. Renard, Jean Frédéric Colombel, Ryan C. Ungaro. Journal of Crohn's and Colitis
- Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). Jean Frederic Colombel, William J. Sandborn, Stefan Schreiber, Silvio Danese, Maria Kłopocka, Jarosław Kierkuś, Roman Kulynych, MacIej Gonciarz, Artur Sołtysiak, Patryk Smoliński, Slobodan Srećković, Ekaterina Valuyskikh, Adi Lahat, Marek Horyński, Antonio Gasbarrini, Marina Osipenko, Vladimir Borzan, MacIej Kowalski, Daria Saenko, Ruslan Sardinov, Sang Joon Lee, Sunghyun Kim, Yunju Bae, Sunhee Lee, Seulgi Lee, Joon Ho Lee, Jong Min Kim, Gahee Park, Jimin Lee, Juhyun Lee, Jae Yeoul Ryu, Bruce E. Sands, Stephen B. Hanauer. Journal of Crohn's and Colitis
Patient Experience Star Ratings and Comments
The Patient Experience Star Rating reflects our patients’ perception of how well their Mount Sinai provider communicated with them during an office visit. The Star Rating is based on patient responses to three questions on a patient experience survey, a standardized questionnaire sent to verified patients and distributed by a third party vendor, Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Care Provider’s Explanation
Care Provider’s Concern
Likelihood to Recommend Care Provider
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Sands during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Tr1X, Inc.
- Fzata
- Boehringer Ingelheim Corporation
- Target RWE
- Equilium, Inc.
- Mitsubishi Tanabe Pharma Corportation
- Teva Branded Pharmaceutical Products R&D, Inc.
- Eli Lilly and Company
- Quotient Therapeutics
- Ono Pharmaceuticals
- Disc Medicine, Inc.
- Palisade Bio, Inc.
- Adiso Therapeutics USA
- Alimentiv
- Rasayana Therapeutics
- AstraZeneca
- Takeda Development Center Americas, Inc.
- Amgen Inc.
- Galapagos
- Bristol-Myers Squibb
- Vividion Therapeutics
- Janssen Pharmaceutica NV
- Morphic Therapeutic
- Odyssey Therapeutics
- Numab Therapeutics
- Genentech, Inc.
- Glaxosmithkline
- WebMD
- Biora Therapeutics
- MJH Healthcare Holdings
- Slate Bio
- Gilead Sciences
- Mobius Care
- Ferring Pharmaceuticals
- Vindico Medical Education
- Vedanta Biosciences
- Celltrion
- Agomab Therapeutics
- Integritas Communications, LLC
- FirstThought
- Materia Prima
- Celltrion USA
- Merck Sharp & Dohme Corp
- AnaptysBio, Inc
- techspert.io
- Abivax
- Nimbus Discovery
- Pfizer
- Imhotex
- Sorriso Therapeutics
- AbbVie Inc.
- MRM Health NV
- EcoR1 Capital
- Q32 Bio Inc.
- Spyre Therapeutics
- Recludix Pharma
- Janssen Research & Development
- Microbiotica Limited
- Trex Bio
- Nexus Therapeutics
- Sanofi US Services Inc.
- Ignite Biomedical
- Ventyx Biosciences
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Ventyx Biosciences
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Sands during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Tr1X, Inc.
- Fzata
- Boehringer Ingelheim Corporation
- Target RWE
- Equilium, Inc.
- Mitsubishi Tanabe Pharma Corportation
- Teva Branded Pharmaceutical Products R&D, Inc.
- Eli Lilly and Company
- Quotient Therapeutics
- Ono Pharmaceuticals
- Disc Medicine, Inc.
- Palisade Bio, Inc.
- Adiso Therapeutics USA
- Alimentiv
- Rasayana Therapeutics
- AstraZeneca
- Takeda Development Center Americas, Inc.
- Amgen Inc.
- Galapagos
- Bristol-Myers Squibb
- Vividion Therapeutics
- Janssen Pharmaceutica NV
- Morphic Therapeutic
- Odyssey Therapeutics
- Numab Therapeutics
- Genentech, Inc.
- Glaxosmithkline
- WebMD
- Biora Therapeutics
- MJH Healthcare Holdings
- Slate Bio
- Gilead Sciences
- Mobius Care
- Ferring Pharmaceuticals
- Vindico Medical Education
- Vedanta Biosciences
- Celltrion
- Agomab Therapeutics
- Integritas Communications, LLC
- FirstThought
- Materia Prima
- Celltrion USA
- Merck Sharp & Dohme Corp
- AnaptysBio, Inc
- techspert.io
- Abivax
- Nimbus Discovery
- Pfizer
- Imhotex
- Sorriso Therapeutics
- AbbVie Inc.
- MRM Health NV
- EcoR1 Capital
- Q32 Bio Inc.
- Spyre Therapeutics
- Recludix Pharma
- Janssen Research & Development
- Microbiotica Limited
- Trex Bio
- Nexus Therapeutics
- Sanofi US Services Inc.
- Ignite Biomedical
- Ventyx Biosciences
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Ventyx Biosciences
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.